(NASDAQ: OCUP) Ocuphire Pharma's forecast annual revenue growth rate of 49.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Ocuphire Pharma's revenue in 2024 is $19,011,000.On average, 1 Wall Street analysts forecast OCUP's revenue for 2024 to be $190,283,320, with the lowest OCUP revenue forecast at $190,283,320, and the highest OCUP revenue forecast at $190,283,320. On average, 1 Wall Street analysts forecast OCUP's revenue for 2025 to be $871,829,434, with the lowest OCUP revenue forecast at $871,829,434, and the highest OCUP revenue forecast at $871,829,434.
In 2026, OCUP is forecast to generate $1,670,293,500 in revenue, with the lowest revenue forecast at $1,670,293,500 and the highest revenue forecast at $1,670,293,500.